Experience of Relatox (botulinum toxin type A) using for chronic migraine treatment
A real-world clinical trial confirmed the efficacy and safety of Relatox for the treatment of chronic migraine. The cumulative effect of Relatox was noted: an increase in effectiveness while following the protocol of administration once every 12 weeks.
Authors
- N.V. Vashchenko
- E. Z. Mamkhegov (ORCID: https://orcid.org/0000-0003-4002-1538)
- A. S. Galanina
- Yu. É. Azimova
- A.V. Frolova
- V.V. Osipova
- N.V. Koptenko
- E.A. Guziy
- D.Z. Korobkova
- A.S. Bazhenova
- K.V. Skorobogatykh
- E.V. Noskov
Institutions
- University Clinic of Traumatology (AT)
- Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences (RU)
- University Dermatology (US)
- University Radiology (US)
Publication Details
- Journal
- S S Korsakov Journal of Neurology and Psychiatry
- Published
- 2025-12-30
- DOI
- https://doi.org/10.17116/jnevro2025125121134
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00